Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Lung Cancer|Pulmonary Cancer|Non-Small-Cell Lung Carcinoma|Prostate Cancer|Prostatic Cancer|Gastric Cancer|Stomach Cancer
Interventions: DRUG: MGCD0103 & Docetaxel
Sponsor: Mirati Therapeutics Inc.